Gastrointestinal side effects in postmenopausal women using osteoporosis therapy: 1-year findings in the POSSIBLE US study

Current Medical Research and Opinion

Volumn 26, Issue 4, 2010, Pages 1003-1009

  Woo, Claudine ^a   Gao, Guozhi ^a   Wade, Sally ^b   Hochberg, Marc C ^c  

^a AMGEN INC   (United States)

^b Wade Outcomes Research and Consulting   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Gastrointestinal side effects; Health related quality of life; Medication discontinuation; Osteoporosis therapy; Treatment satisfaction

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D;

ADULT; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; LOWER ABDOMINAL PAIN; MAJOR CLINICAL STUDY; NAUSEA; ODYNOPHAGIA; PATIENT SATISFACTION; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; QUESTIONNAIRE; STOMACH PAIN; UPPER ABDOMINAL PAIN;

AGED; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; CALCIUM; DIPHOSPHONATES; ESTROGEN REPLACEMENT THERAPY; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS; PARATHYROID HORMONE; PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUALITY OF LIFE; REGRESSION ANALYSIS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; UNITED STATES;

EID: 77949527094     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003633603     Document Type: Article

References (19)

1. National Osteoporosis Foundation. Fast facts of osteoporosis. Available at: http://www.nof.org/osteoporosis/diseasefacts.htm#prevalence [Last accessed 11 December 2009]
2. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:465-475
3. US Dept of Health and Human Services Office of the Surgeon General. Bone Health and Osteoporosis: A Report of the Surgeon General 2004. Available at: http://www.surgeongeneral.gov/library/bonehealth/docs/full-report.pdf [last accessed 11 December 2009]
4. Top 200 Brand Drugs by Units in 2007. Drug Topics, 2008. Available at: http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard// drugtopics/072008/491207/article.pdf [last accessed 11 December 2009]
5. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008;148:197-213
6. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008:CD001155
7. Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008:CD004523
8. Emkey RD, Ettinger M. Improving compliance and persistence with bispho-sphonate therapy for osteoporosis. Am J Med 2006;119:S18-24
9. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003;14:259-262
10. TM Study: postmenopausal women's compliance and persistence with osteoporosis medications. Osteoporos Int 2009;20:463-472
11. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-72
12. Silverman SL. The osteoporosis assessment questionnaire (OPAQ): a reliable and valid disease-targeted measure of health related quality of life (HRQoL) in osteoporosis. Qual Life Res 2000;9:767-774
13. Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004;2:12
14. Taggart H, Bolognese MA, Lindsay R, et al. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 2002;77:262-270
15. Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000; 160:517-525
16. Grima D, Ioannidis G, Papaioannou A, et al. Treatment discontinuation due to gastrointestinal adverse events and decreased bone mineral density in patients switched from branded alendronate to generic alendronate. J Bone Miner Res 2008;23(S1):S210
17. Ringe JD, Moller G. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postme-nopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 2009:30:213-221
18. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendro-nate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000;12:1-12
19. Harris ST, Watts NB, Li Z, et al. Two-year efficacy and tolerability of risedro-nate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 2004;20:757-764